rPOC-752

N/A

Report date: 2023/07/31 17:26:42

Base Information

Drug NamerPOC-752
Drug Alias NamerPOC-752
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD22 modulators
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesExuma Biotech Corp
China Registration ClassN/A

Develop Information

Active CompaniesExuma Biotech Corp
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A